FinVector
FinVector Oy is a Finnish cGMP biopharmaceutical manufacturer specializing in adenoviral gene therapy drug substance production, primarily for its sole commercial customer Ferring Pharmaceuticals' FDA-approved bladder cancer therapy Adstiladrin, operated from a 25,000 sqm facility in Kuopio, Finland.
- Company typePrivate
- Founded1993
- HeadquartersKuopio, Finland
- Headcount101–250
- GTM typeB2B
- OfferingServices
What FinVector does
FinVector Oy is a Finnish cGMP biopharmaceutical manufacturer specializing in viral-based gene therapy products, headquartered in Kuopio, Finland. Founded in 1993 as one of the world's first gene therapy companies, FinVector operates as a wholly-owned subsidiary of Swiss-based Ferring Ventures S.A. The company's core product is Adstiladrin (nadofaragene firadenovec-vncg), an adenovirus-based gene therapy that received FDA approval in December 2022 for the treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. FinVector manufactures the viral vector drug substance for Ferring Pharmaceuticals, which handles global commercialization and distribution.
FinVector's manufacturing platform is built on three decades of cGMP experience in adenoviral gene therapy, with end-to-end capabilities spanning solution preparation, cell cultivation, virus generation, purification, and drug product formulation. The company holds both FDA and EMA/FIMEA regulatory approvals for clinical and commercial production. In October 2024, FinVector opened Finport, a state-of-the-art 25,000 square meter manufacturing facility in Kuopio's Savilahti district, equipped with Pall Corporation's iCELLis bioreactor platform and sustainable energy systems; the facility is described as one of the world's largest viral vector manufacturing capacities.
The business model is B2B contract manufacturing within the Ferring Group ecosystem. FinVector generates revenue by manufacturing drug substance for Ferring Pharmaceuticals' gene therapy portfolio, with the relationship structured through Ferring Ventures S.A., which also owns the R&D-focused Kuopio Center for Gene and Cell Therapy (now Ferring Ventures Oy). Pricing and contract terms are not publicly disclosed. Revenue streams are highly concentrated, as Ferring Pharmaceuticals is essentially the sole commercial customer. The company has secured substantial growth capital, including a EUR 45 million NIB loan, EUR 6.555 million ELY Centre grant, and over EUR 600 million of cumulative Ferring Group investment since 2014, and has scaled headcount to approximately 500 employees across more than 50 nationalities as of October 2024.
FinVector firmographics
Firmographics- Name
- FinVector
- Legal name
- FinVector Oy
- Website
- https://finvector.com
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- FinVector Oy is a Finnish cGMP biopharmaceutical manufacturer specializing in adenoviral gene therapy drug substance production, primarily for its sole commercial customer Ferring Pharmaceuticals' FDA-approved bladder cancer therapy Adstiladrin, operated from a 25,000 sqm facility in Kuopio, Finland.
- Ownership category
- akta.pro rank
FinVector industry classification
Industry- Product category
- Biopharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where FinVector is headquartered
LocationHeadquarters
- HQ city
- Kuopio
- HQ country
- Finland
- HQ region
- Europe
Offices2 records
Markets served
FinVector business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain
Revenue model
- Contract manufacturing of viral vector-based gene therapy drug substance: FinVector manufactures the drug substance for Ferring Pharmaceuticals' FDA-approved gene therapy Adstiladrin. As a subsidiary of Ferring Ventures SA, FinVector operates as a manufacturing and R&D hub within the Ferring group, producing pharmaceutical products that are commercialized globally by Ferring Pharmaceuticals. Revenue is generated through product manufacturing and potentially through licensing/partnership arrangements within the Ferring group.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
FinVector product offering
Product offeringCore offering
FinVector is a cGMP contract manufacturer of viral-based gene therapy products. The company manufactures the viral vector drug substance for Ferring Pharmaceuticals' FDA-approved gene therapy Adstiladrin (nadofaragene firadenovec-vncg) used to treat high-risk BCG-unresponsive non-muscle invasive bladder cancer. Production covers the full pipeline from solution preparation and cell cultivation through virus generation, purification, and drug product formulation at the Finport facility in Kuopio, Finland.
Product overview
FinVector is a cGMP biopharmaceutical manufacturer specializing in viral-based gene therapy products. The company's core offering consists of the FDA-approved Adstiladrin gene therapy for bladder cancer, manufactured at their state-of-the-art Finport facility using the adenovirus-based viral vector platform. Their manufacturing services span the entire production process including solution preparation, drug substance manufacturing (cell cultivation, virus generation, purification), and drug product formulation. The company operates from Savilahti, Kuopio, Finland and is a subsidiary of Ferring Ventures SA.
Differentiator
Problem solved
Functional benefit
Products and services
- Adstiladrin (nadofaragene firadenovec-vncg) drug substance
- cGMP Viral Vector Manufacturing Services
Quantifiable outcome
- FDA approval of Adstiladrin (nadofaragene firadenovec-vncg) as a first-in-class viral-based gene therapy for bladder cancer
- +3 more outcomes
Companies that use FinVector
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
FinVector technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
FinVector partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, flagship and minor.
- City of KuopiocoreFinVector acquired two plots of land from the City of Kuopio in the Savilahti area for nearly EUR 3.9 million, totaling approximately 1.6 hectares. One plot hosts the new Finport manufacturing facility and the other is reserved for future expansion. The City of Kuopio has been a supportive partner, proposing state honors for FinVector executives and supporting the company's growth in the region.
- University of Eastern Finland (UEF)coreFinVector and the University of Eastern Finland signed a memorandum of understanding committing to a long-term strategic partnership. Collaboration spans research, education, and workforce development. FinVector offers students thesis projects and internships while working with UEF on programs like the ReguVa project developing regulatory and responsibility expertise. The partnership leverages UEF's internationally recognized gene and cell therapy research.
- Ferring PharmaceuticalsflagshipFerring Pharmaceuticals is the sister company and primary commercial partner of FinVector. FinVector manufactures the drug substance for Ferring's FDA-approved gene therapy Adstiladrin (nadofaragene firadenovec-vncg) for bladder cancer, which Ferring commercializes globally. Both companies are part of the Ferring Ventures SA consortium. The relationship is deeply integrated with shared R&D, manufacturing, and commercialization objectives.
- Pall CorporationcoreFinVector utilizes the iCELLis manufacturing platform from Pall Corporation in its Finport facility. This platform enables large-scale viral vector production, making Finport one of the world's largest viral vector manufacturing facilities. The iCELLis system is a key component of FinVector's production technology for gene therapy drug substance.
- Savo Vocational College (Sakky)coreFinVector partners with Savo Vocational College to deliver joint RekryKoulutus (recruitment training) programs that prepare participants for biopharmaceutical manufacturing roles at FinVector. The training combines theoretical teaching at the college's Savilahti campus with on-the-job learning at FinVector's facilities. Successful graduates are offered permanent employment contracts.
- Kuopio Center for Gene and Cell Therapy (KCT)coreBoth FinVector and KCT are 100% owned by Ferring Ventures SA. KCT conducts R&D in cell and gene therapy and draws from the pioneering research of Professor Seppo Ylä-Herttuala. The two companies collaborate closely, sharing the Kuopio-based research ecosystem and complementary capabilities in manufacturing and R&D.
- Rakennusliike U. Lipsanen OyminorRakennusliike U. Lipsanen Oy served as the main contractor for the construction of Finport. The company completed construction on schedule, handing over the keys to the facility at the beginning of April 2024.
Scale indicators11 records
Recent moves9 records
Expansion highlights5 records
FinVector competitors and assessment
Company assessmentBroad incumbents
- Lonza: Global CDMO leader with large-scale viral vector and cell therapy manufacturing capabilities across multiple sites. Direct competitor for any third-party gene therapy manufacturing contracts FinVector may pursue beyond Ferring's captive needs.
- Catalent: Major CDMO with gene therapy manufacturing capacity and viral vector capabilities through its Paragon and MaSTherCell units. Competes with FinVector for gene therapy contract manufacturing opportunities globally.
- Charles River Laboratories: Provides viral vector CDMO services through its acquisition of Cobra Biologics and other gene therapy manufacturing assets. Competes in viral vector contract manufacturing with comparable service offerings.
- Thermo Fisher Scientific (Patheon): Operates extensive CDMO capabilities including viral vector manufacturing through its pharma services division. Competes for gene therapy contract manufacturing clients at global scale.
- Samsung Biologics: South Korean-based large-scale CDMO expanding into viral vector and gene therapy manufacturing. Represents competitive pressure in CDMO market, though focused primarily on biologics today.
- WuXi AppTec (Advanced Therapies): Large Chinese CDMO with viral vector and cell therapy manufacturing capabilities. Competes globally for gene therapy contract manufacturing business, though geopolitical considerations may limit overlap with FinVector's customer base.
- Fujifilm Diosynth Biotechnologies: CDMO with viral vector manufacturing capabilities and significant European presence. Provides comparable gene therapy contract manufacturing services to pharmaceutical sponsors globally.
Direct peers
- Yposkesi: French viral vector CDMO specializing in AAV and lentiviral production for gene therapy. Closely comparable business model as a specialized viral vector manufacturer serving pharmaceutical clients, though focused on different vector types than FinVector's adenoviral platform.
- Kaneka Eurogentec: Belgian-Japanese CDMO with viral vector manufacturing services including adenovirus, AAV, and plasmid production. Most directly comparable to FinVector as a specialized viral vector manufacturer of similar scale and European base.
Others
- uniQure: Gene therapy developer with proprietary AAV-based manufacturing platform rather than a CDMO, but shares FinVector's pioneering gene therapy commercial approval profile and vertical integration of manufacturing capabilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks1 record
Key highlights6 records
Customer concentration
FinVector social profiles
Digital presenceFinVector compliance and trust
Trust signalCompliance5 records
FinVector financial estimates
Financial estimateRevenue estimate
Valuation estimate
FinVector leadership team
Management profileNumber of profiles
Profiles10 records
FinVector funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FinVector M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FinVector
What does FinVector do?
FinVector is a cGMP contract manufacturer of viral-based gene therapy products. The company manufactures the viral vector drug substance for Ferring Pharmaceuticals' FDA-approved gene therapy Adstiladrin (nadofaragene firadenovec-vncg) used to treat high-risk BCG-unresponsive non-muscle invasive bladder cancer. Production covers the full pipeline from solution preparation and cell cultivation through virus generation, purification, and drug product formulation at the Finport facility in Kuopio, Finland.
Is FinVector a public or private company?
FinVector is a private company. It is classified as corporate owned and is currently operating.
When was FinVector founded?
FinVector was founded in 1993. It employs 101 to 250 people.
Where is FinVector based?
FinVector is headquartered in Kuopio, Finland, in the Europe region.
How does FinVector make money?
One revenue line is on record: contract manufacturing of viral vector-based gene therapy drug substance.
Who are FinVector's main competitors?
Broad incumbents on record are Lonza, Catalent, Charles River Laboratories, Thermo Fisher Scientific (Patheon), Samsung Biologics, WuXi AppTec (Advanced Therapies) and Fujifilm Diosynth Biotechnologies. Direct peers are Yposkesi and Kaneka Eurogentec. uniQure is listed as an others.
Does FinVector have an API?
No public API is recorded for FinVector.
What industry is FinVector in?
FinVector's product category is Biopharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 325412 and its SIC code is 2834.